Quantum: FDA Approves IND For Lucid-MS; To Engage CRO To Support Implementation Of Phase 2 Study

August 10, 2026 — 07:47 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Quantum BioPharma (QNTM) announced the FDA has approved the company's Investigational New Drug application for Lucid-MS, enabling Quantum BioPharma to immediately advance its patented, multiple sclerosis program into Phase 2 clinical development. The company said it is working with a global clinical research organization with significant experience in neurodegenerative studies, to support implementation of the planned Phase 2 study. The company expects to initiate patient enrollment and drug administration as quickly as possible.

Quantum BioPharma noted that it maintains a strong balance sheet to support clinical development programs. The company reported cash, digital assets and liquid investments totaling over $10 million as of March 31, 2026.

In pre-market trading on NasdaqCM, Quantum BioPharma shares are down 6.38 percent to $3.23.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Quantum: FDA Approves IND For Lucid-MS; To Engage CRO To Support Implementation Of Phase 2 Study

Tags

Latest Articles